SCHEMBL25379029

SCHEMBL25379029

COc1ccc(Cc2nccc3c(N)c(C)ccc23)cc1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PDE10A Q9Y233 4/20 0.53
▸ PDE3B Q13370 3/20 0.53
▸ PDE3A Q14432 3/20 0.53
▸ POLB P06746 1/20 0.42
▸ ALDH1A1 P00352 5/20 0.41
▸ CYP2D6 P10635 2/20 0.41
▸ ATM Q13315 1/20 0.41
▸ ROCK1 Q13464 2/20 0.40
▸ LMNA P02545 4/20 0.40
▸ KDR P35968 2/20 0.40
▸ HPGD P15428 2/20 0.40
▸ SMN1; SMN2 Q16637 3/20 0.39
▸ NPSR1 Q6W5P4 2/20 0.39
▸ USP2 O75604 2/20 0.39
▸ CYP3A4 P08684 2/20 0.39
▸ MAPK1 P28482 2/20 0.39
▸ HIF1A Q16665 2/20 0.39
▸ RAB9A P51151 2/20 0.39
▸ PDE2A O00408 1/20 0.39
▸ ABCC4 O15439 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30402388 0.83 PARP1 (0.36) PDE10APDE3BPDE3AALDH1A1CYP2D6
SCHEMBL30402640 0.83 FLT1 (0.38) PDE10APDE3BPDE3APOLBALDH1A1
SCHEMBL24399590 0.83 FLT1 (0.38) PDE10APDE3BPDE3APOLBALDH1A1
SCHEMBL24399752 0.83 PARP1 (0.36) PDE10APDE3BPDE3AALDH1A1CYP2D6
SCHEMBL25375372 0.80 MBOAT4 (0.39) ALDH1A1ROCK1LTA4HNPC1
SCHEMBL30401708 0.80 MBOAT4 (0.39) ALDH1A1ROCK1LTA4HNPC1
SCHEMBL25377549 0.79 PDE3B (0.48) PDE10APDE3BPDE3APOLBALDH1A1
SCHEMBL1743766 0.77 PDE3B (0.54) PDE10APDE3BPDE3APOLBALDH1A1
SCHEMBL26373752 0.76 PDE3B (0.41) PDE3BPDE3APOLBALDH1A1LMNA
SCHEMBL25374966 0.75 KLKB1 (0.39) —

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230312556-A1 ARYLAMIDE COMPOUND, PHARMACEUTICAL COMPOSITION COMPRISING SAME, AND PREPARATION METHOD THEREFOR AND USE THEREOF SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD. (CN) 2023-10-05 — — US disclosed
US-20230312556-A1 ARYLAMIDE COMPOUND, PHARMACEUTICAL COMPOSITION COMPRISING SAME, AND PREPARATION METHOD THEREFOR AND USE THEREOF SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD. (CN) 2023-10-05 — — US disclosed
US-20230312556-A1 ARYLAMIDE COMPOUND, PHARMACEUTICAL COMPOSITION COMPRISING SAME, AND PREPARATION METHOD THEREFOR AND USE THEREOF SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD. (CN) 2023-10-05 — — US disclosed
EP-4238967-A1 ARYLAMIDE COMPOUND, PHARMACEUTICAL COMPOSITION COMPRISING SAME, AND PREPARATION METHOD THEREFOR AND USE THEREOF Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (CN) 2023-09-06 — — EP disclosed
EP-4238967-A1 ARYLAMIDE COMPOUND, PHARMACEUTICAL COMPOSITION COMPRISING SAME, AND PREPARATION METHOD THEREFOR AND USE THEREOF Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (CN) 2023-09-06 — — EP disclosed
CN-116096718-A Aryl amide compound, pharmaceutical composition containing same, preparation method and application thereof 四川科伦博泰生物医药股份有限公司 2023-05-09 — — CN disclosed
WO-2022089219-A1 ARYLAMIDE COMPOUND, PHARMACEUTICAL COMPOSITION COMPRISING SAME, AND PREPARATION METHOD THEREFOR AND USE THEREOF 四川科伦博泰生物医药股份有限公司 2022-05-05 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230312556-A1 ARYLAMIDE COMPOUND, PHARMACEUTICAL COMPOSITION COMPRISING SAME, AND PREPARATION METHOD THEREFOR AND USE THEREOF AHR, ARNT, NOTUM PDE10A 734/4885PDE3B 1633/4885PDE3A 1344/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback